The balance of tissue repair and remodeling in chronic arthritis

Nature Reviews Rheumatology

Volumn 7, Issue 12, 2011, Pages 700-707

  Lories, Rik ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

WNT PROTEIN;

ANKYLOSING SPONDYLITIS; APOPTOSIS; BONE REMODELING; CELL DAMAGE; CELL STRESS; CHRONIC ARTHRITIS; COPING BEHAVIOR; DISEASE COURSE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE METABOLISM; TISSUE REPAIR;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE REMODELING; HUMANS; JOINTS; SPONDYLITIS, ANKYLOSING;

EID: 82955233020     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.156     Document Type: Review

References (78)

1. Klareskog, L., Catrina, A. I. & Paget, S. Rheumatoid arthritis. Lancet 373, 659-672 (2009).
2. Braun, J. & Sieper, J. Ankylosing spondylitis. Lancet 369, 1379-1390 (2007). (Pubitemid 46590387)
3. Mease, P. J. Psoriatic arthritis: Update on pathophysiology, assessment and management. Ann. Rheum. Dis. 70 (Suppl. 1), i77-i84 (2011).
4. McInnes, I. B. & O'Dell, J. R. State-of-the-Art: Rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898-1906 (2010).
5. Brandt, H. C., Spiller, I., Song, I.-H., Vahldiek, J. L., Rudwaleit, M. & Sieper, J. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann. Rheum. Dis. 66, 1479-1484 (2007). (Pubitemid 350032656)
6. Luyten, F. P., Lories, R. J. U., Verschueren, P., de Vlam, K. & Westhovens, R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 20, 829-848 (2006). (Pubitemid 44356463)
7. Schett, G. Joint remodelling in inflammatory disease. Ann. Rheum. Dis. 66 (Suppl. 3), iii42-iii44 (2007). (Pubitemid 350032632)
8. Lories, R. J. U., Luyten, F. P. & de Vlam, K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res. Ther. 11, 221 (2009).
9. El-Maghraoui, A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71, 291-295 (2004).
10. Carter, S. Lories, R. J. Osteoporosis: A paradox in ankylosing spondylitis. Current Osteoporos. Rep. 9, 112-115 (2011).
11. Lories, R. J. U., de Vlam, K. & Luyten, F. P. Are current available therapies disease-modifying in spondyloarthritis?. Best. Pract. Res. Clin. Rheumatol. 24, 625-635 (2010).
12. Machado, P. et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann. Rheum. Dis. 69, 1465-1470 (2010).
13. Vander Cruyssen, B. et al. Hip involvement in ankylosing spondylitis: Epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 49, 73-81 (2010).
14. Vandooren, B. et al. Mediators of structural remodeling in peripheral spondylarthritis. Arthritis Rheum. 60, 3534-3545 (2009).
15. Cross, M. J., Smith, E. U. R., Zochling, J. & March, L. M. Differences and similarities between ankylosing spondylitis and rheumatoid arthritis: Epidemiology. Clin. Exp. Rheumatol. 27, S36-S42 (2009).
16. Boonen, A. & Mau, W. The economic burden of disease: Comparison between rheumatoid arthritis and ankylosing spondylitis. Clin. Exp. Rheumatol. 27, S112-S117 (2009).
17. Sieper, J., Appel, H., Braun, J. & Rudwaleit, M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. Arthritis Rheum. 58, 649-656 (2008). (Pubitemid 351364862)
18. Lories, R. J. U., Derese, I. & Luyten, F. P. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford) 47, 605-608 (2008). (Pubitemid 351619197)
19. Schett, G. et al. Tumor necrosis factor a and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum. 60, 2644-2654 (2009).
20. Maksymowych, W. P. Disease modification in ankylosing spondylitis. Nat. Rev. Rheumatol. 6, 75-81 (2010).
21. Appel, H. et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 54, 1805-1813 (2006). (Pubitemid 43877930)
22. Appel, H. et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J. Rheumatol. 37, 823-828 (2010).
23. Bywaters, E. G. The early lesions of ankylosing spondylitis. Ann. Rheum. Dis. 28, 330 (1969).
24. Fraņois, R. J., Gardner, D. L., Degrave, E. J. & Bywaters, E. G. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. 43, 2011-2024 (2000).
25. Fraņois, R. J., Braun, J. & Khan, M. A. Entheses and enthesitis: A histopathologic review and relevance to spondyloarthritides. Curr. Opin. Rheumatol. 13, 255-264 (2001). (Pubitemid 32831815)
26. Karsenty, G., Kronenberg, H. M. & Settembre, C. Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 25, 629-648 (2009).
27. Lories, R. J. U. & Luyten, F. P. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res. Ther. 9, 207 (2007).
28. Lories, R. J. U., Matthys, P., de Vlam, K., Derese, I. & Luyten, F. P. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: A model of psoriatic arthritis. Ann. Rheum. Dis. 63, 595-598 (2004). (Pubitemid 38530208)
29. Zimmerman, L. B., De Jesús-Escobar, J. M. Harland, R. M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86, 599-606 (1996). (Pubitemid 26299491)
30. Lories, R. J. U., Derese, I. & Luyten, F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 115, 1571-1579 (2005). (Pubitemid 40814665)
31. Lories, R. J. U. et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 54, 1736-1746 (2006). (Pubitemid 43877923)
32. Milat, F. & Ng, K. W. Is Wnt signalling the final common pathway leading to bone formation? Mol. Cell. Endocrinol. 310, 52-62 (2009).
33. Liu, F., Kohlmeier, S. & Wang, C.-Y. Wnt signaling and skeletal development. Cell Signal 20, 999-1009 (2008).
34. Lories, R. J. & Luyten, F. P. Osteoimmunology: Wnt antagonists: For better or worse? Nat. Rev. Rheumatol. 5, 420-421 (2009).
35. Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis. Bone 44, 522-527 (2009).
36. Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156-163 (2007).
37. Uderhardt, S. et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. 69, 592-597 (2010).
38. van Beuningen, H. M., Glansbeek, H. L., van der Kraan, P. M. & van den Berg, W. B. Differential effects of local application of BMP-2 or TGF-ß1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage 6, 306-317 (1998). (Pubitemid 28404971)
39. Scharstuhl, A., Vitters, E. L., van der Kraan, P. M. & van den Berg, W. B. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor ß/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum. 48, 3442-3451 (2003). (Pubitemid 37531910)
40. Lories, R. J. U., Derese, I., de Bari, C. & Luyten, F. P. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 56, 489-497 (2007).
41. van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063-3070 (2008).
42. van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324-1331 (2008). (Pubitemid 351705922)
43. van der Heijde, D. et al. Canadian (M03-606) study group & ATLAS study group Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).
44. Braun, J. & Baraliakos, X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann. Rheum. Dis. 70 (Suppl. 1), i97-i103 (2011).
45. Spoorenberg, A. et al. Measuring disease activity in ankylosing spondylitis: Patient and physician have different perspectives. Rheumatology (Oxford) 44, 789-795 (2005). (Pubitemid 41487211)
46. Maksymowych, W. P. Progress in spondylarthritis. Spondyloarthritis: Lessons from imaging. Arthritis Res. Ther. 11, 222 (2009).
47. Sieper, J. et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 44, 1525-1530 (2005). (Pubitemid 41742469)
48. Maksymowych, W. P. et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: Evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 60, 93-102 (2009).
49. Lu, X. et al. Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor a action in osteoblast differentiation. J. Bone Miner. Res. 26, 209-219 (2011).
50. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-Associated immunopathologies. Immunity 10, 387-398 (1999). (Pubitemid 29165293)
51. Kaplan, F. S. et al. Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 22, 191-205 (2008). (Pubitemid 351325734)
52. Shore, E. M. et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38, 525-527 (2006).
53. Fukuda, T. et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis 44, 159-167 (2006). (Pubitemid 43727738)
54. Yu, P. B. et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 14, 1363-1369 (2008).
55. Colbert, R. A., DeLay, M. L., Klenk, E. I. & Layh-Schmitt, G. From HLA-B27 to spondyloarthritis: A journey through the ER. Immunol. Rev. 233, 181-202 (2010).
56. Benjamin, M. & McGonagle, D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv. Exp. Med. Biol. 649, 57-70 (2009).
57. McGonagle, D., Lories, R. J. U., Tan, A. L. & Benjamin, M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 56, 2482-2491 (2007). (Pubitemid 47237267)
58. Baraliakos, X., Listing, J., von der Recke, A. & Braun, J. The natural course of radiographic progression in ankylosing spondylitis-evidence for major individual variations in a large proportion of patients. J. Rheumatol. 36, 997-1002 (2009).
59. Chen, H. A. et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J. Rheumatol. 37, 2126-2132 (2010).
60. Tsukahara, S. et al. COL6A1, the candidate gene for ossification of the posterior longitudinal ligament, is associated with diffuse idiopathic skeletal hyperostosis in Japanese. Spine (Phila Pa 1976) 30, 2321-2324 (2005) (Pubitemid 41504903)
61. Thomas, G. P. & Brown, M. A. Genetics and genomics of ankylosing spondylitis. Immunol. Rev. 233, 162-180 (2010).
62. Wanders, A. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum. 52, 1756-1765 (2005). (Pubitemid 40852884)
63. Daoussis, D. et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 62, 150-158 (2010).
64. Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883-19887 (2005). (Pubitemid 41379516)
65. Appel, H. et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60, 3257-3262 (2009).
66. Herman, S., Krönke, G. & Schett, G. Molecular mechanisms of inflammatory bone damage: Emerging targets for therapy. Trends Mol. Med. 14, 245-253 (2008).
67. Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233-255 (2010).
68. Parsonage, G., Filer, A. D., Haworth, O., Nash, G. B., Rainger, G. E., Salmon, M. & Buckley, C. D. A stromal address code defined by fibroblasts. Trends Immunol. 26, 150-156 (2005). (Pubitemid 40312522)
69. Walsh, N. C. & Gravallese, E. M. Bone remodeling in rheumatic disease: A question of balance. Immunol. Rev. 233, 301-312 (2010).
70. Schett, G. & David, J.-P. The multiple faces of autoimmune-mediated bone loss. Nat. Rev. Endocrinol. 6, 698-706 (2010).
71. Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008). (Pubitemid 351705919)
72. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
73. Scott, D. L., Wolfe, F. & Huizinga, T. W. J. Rheumatoid arthritis. Lancet 376, 1094-1108 (2010).
74. Døhn, U. M. et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: Results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann. Rheum. Dis. 70, 252-258 (2011).
75. Walsh, N. C. et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner. Res. 24, 1572-1585 (2009).
76. Aletaha, D., Funovits, J. & Smolen, J. S. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann. Rheum. Dis. 70, 733-739 (2011).
77. Benjamin, M. & McGonagle, D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J. Anat. 199, 503-526 (2001). (Pubitemid 33094612)
78. Sieber, C., Kopf, J., Hiepen, C. & Knaus, P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 20, 343-355 (2009).